New partnership announcement: Sciensus partners with Sentynl Therapeutics, Inc. to become the exclusive distribution partner of NULIBRY® (fosdenopterin) in Europe. Sciensus will deliver both an early access programme and distribution services to support the market access and reimbursement processes of NULIBRY® in Europe. "In partnership with Sciensus, we are proud to extend the reach of this innovative treatment to meet the needs of patients with MoCD Type A in Europe. This partnership marks another step forward in our mission to expand patient access to life-changing rare disease treatment.” said Matt Heck, President & Chief Executive Officer of Sentynl. To read the full press release, visit: https://lnkd.in/er5F4SEY #Sentynl #Partnership #RareDiseases #OrphanDrugs #EAP #expandedaccessprogrammes #insights
Sciensus - Rare Disease Services
Pharmaceutical Manufacturing
Sciensus is a life sciences business dedicated to getting rare diseases medicines to hard-to-reach patients in Europe.
About us
Sciensus is a life sciences business specialising in patient access, engagement and insight solutions. Our team has extensive experience in the rare and orphan disease market, and is committed to getting rare medicines to hard-to-reach patients in Europe and beyond. For over 30 years, we’ve delivered on every aspect of this vital transaction; from early access all the way to full commercialization, including patient support programs. With extensive experience behind us, we’re not daunted by the complexities of language, red tape or local rules and regulations. Instead, we work day and night to get your life-changing medicine to every patient, everywhere. Our team has extensive experience in the rare and orphan disease market, including: - The ability to quickly scale your business outside the US. - Local regulatory expertise to keep you and your product safe and compliant through strong central governance on patient activities, PV, PQC. - An established network of existing customers, across 28 markets in Europe, within hospital, pharmacy, clinics and wholesalers. - In-depth knowledge for identifying the patients who are waiting for life saving drugs. - Highly adaptable Patient Support Programme to ensure we’re supporting patients that are on your medication, across all European countries. Over the last 12 months alone, we’ve bought and sold over €350 million of orphan drugs and helped 10,000 patients. Learn more at: https://www.sciensus.com/rare/
- Website
-
https://www.sciensus.com/en-us/rare/
External link for Sciensus - Rare Disease Services
- Industry
- Pharmaceutical Manufacturing
- Company size
- 1,001-5,000 employees
- Headquarters
- London
Updates
-
For biotech companies seeking to bring a new rare disease treatment to market in Europe, there can be many obstacles to overcome. More companies are now turning to expanded access program (EAPs) to get these life-saving drugs to patients who often have no other treatment options. Andrew Cummins, has identified six key steps biotechs must follow to ensure a successful expanded access program in Europe. Find out more here: https://lnkd.in/dkAmpFp9 #EAP #RareDiseases #OrphanDrugs #ExpandedAccessPrograms
Six steps for a successful Expanded Access Program in Europe - Sciensus
-
At Sciensus, we recognize that finding patients in Europe who can benefit from your rare disease medication requires a bespoke approach. Our vast experience tells us that each disease and drug present unique challenges and every country in the region has different regulations governing how pharma companies can market and promote their products. We offer a range of services to support you in expanding access to patients right across Europe. Learn more at: https://lnkd.in/e5-i2fth #RareDiseases #OrphanDrugs #MarketAccess #Biotech
-
In our most recent blog discover the latest insights on the EMA's Orphan Drug Designation and its impact on rare disease treatments. Our latest blog post breaks down the criteria, benefits, and what this means for the pharmaceutical industry and the future of orphan drugs in Europe. Learn more at: https://lnkd.in/eTUbQ2FX #RareDiseases #OrphanDrugs #Biotech
-
Europe has 27 countries, 24 languages and various healthcare systems, regulations, and reimbursement mechanisms. Navigating Europe's diverse landscape can be challenging for US biotech and pharma companies aiming to launch a new orphan drug. Learn about the pros and cons of the three main strategies for biotechs entering the European market: 1. Outlicensing 2. Going solo 3. Partnering Learn more at: https://lnkd.in/eP6VsGjD #RareDiseases #OrphanDrugs #MarketAccess #Biotech
-
Launching a new orphan drug in Europe can be a daunting prospect. The 27 nations which make up the EU bring 24 different languages, and almost as many diverse cultures, healthcare systems, reimbursement approaches, and regulatory landscapes. For any biotech company looking to gain a foothold in the European market, an understanding of these differences, particularly of the European rare disease medicine regulatory system, is essential. To find out how Sciensus can help you overcome regulatory hurdles and expand access to rare and orphan medications in Europe and beyond, visit: https://lnkd.in/exzg69ka #RareDiseases #OrphanDrugs #Biotechs
-
An introduction to post-authorization safety (PASS) studies. Learn about the purpose of PASS in monitoring long-term safety and effectiveness to ensure ongoing patient safety and drug efficacy. Visit: https://lnkd.in/gRnY6rz2 #RareDiseases #OrphanDrugs #Biotechs
-
Expanded access programs (EAPs) for rare disease medications present a valuable opportunity for biotechs to collect real-world data (RWD). In enabling patients to access promising treatments outside of clinical trials, EAPs offer a unique setting to gather data on how therapies perform in diverse, real-world populations. However, several key considerations must be addressed to ensure your RWD collection succeeds. Andrew Cummins explores the collection of real-world data in your EAP, visit: https://lnkd.in/eDhn5d92 #EAP #RareDiseases #OrphanDrugs #ExpandedAccessPrograms #RealWorldData
-
Sciensus’ team has extensive experience in the rare and orphan disease market, supported by a proven 30-year track record in European market expansion. Andrew Cummins shares his insights on how our Expanded Access Programs (EAPs) benefit biotech companies. To learn more about our EAP services, visit: https://lnkd.in/gBzNmGyv #EAP #expandedaccessprograms #rarediseases #orphandrugs
-
For biotech companies seeking to bring a new rare disease treatment to market in Europe, there can be many obstacles to overcome. More companies are now turning to expanded access program (EAPs) to get these life-saving drugs to patients who often have no other treatment options. A well-structured EAP can address unmet medical needs and form part of a strategic commercial launch. Discover the six essential steps for a successful EAP in Europe, visit: https://lnkd.in/dkAmpFp9 #Biotech #RareDiseases #ExpandedAccess #EAP #OrphanDrugs